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Abstract
Background: While rheumatic mitral stenosis has been effectively treated percutaneously for more than 20 years,
mitral and tricuspid regurgitation treatment appear as a contemporary unmet need. The advent of transcatheter
therapies offer new treatment options to often elderly and frail patients at high risk for open surgery. We aimed at
providing an updated review of fast-growing domain of transcatheter mitral and tricuspid technology.
Main body: We reviewed the existing literature on mitral and tricuspid transcatheter therapies. Mitraclip is becoming an
established therapy for secondary mitral regurgitation in selected patients with disproportionately severe regurgitation
associated with moderate left ventricle dysfunction. Evidence is less convincing for primary mitral regurgitation. Transcatheter
mitral valve replacement is a promising emerging alternative to transcatheter repair, for secondary as well as primary mitral
regurgitation. But further development is needed to improve delivery. Transcatheter tricuspid intervention arrives late after
similar technologies have been developed for aortic and mitral valves and is currently at its infancy. This is likely due in part
to previously under-recognized impact of tricuspid regurgitation on patient outcomes. Edge-to-edge repair is the most
advanced transcatheter solution in development. Data on tricuspid annuloplasty and replacement is limited, and more
research is warranted.
Conclusion: The future appears bright for transcatheter mitral therapies, albeit their place in clinical practice is yet to be
clearly defined. Tricuspid transcatheter therapies might address the unmet need of tricuspid regurgitation treatment.
Keywords: TMVI, TMVR, TTVI, Transcatheter mitral therapy, Transcatheter tricuspid therapy, Mitral repair, Mitral replacement,
Tricuspid repair, Tricuspid replacement
Background
Valvular heart disease (VHD) is one the most frequent
pathologies treated with cardiac surgery in western coun-
tries. Interventional and surgical treatment remains the
cornerstone of VHD treatment. Mitral stenosis is less fre-
quent than mitral regurgitation (MR) in developed coun-
tries. MR was reported to be present in > 1% of Western
type population after 70 years old and associated with an
increased mortality [1]. Mitral valve surgery represents
one tenth of all surgical procedures but this remains insuf-
ficient to address the challenge of interventional treatment
of mitral valve disease [2–5]. The incidence of significant
tricuspid regurgitation (TR) after 70 years old is > 5% of
the population. Moderate or severe TR has been incrimi-
nated to be responsible with long-term mortality, but is
infrequently treated with surgery or percutaneous inter-
vention [6–8]. It represents the most common pathology
of the tricuspid valve, and TR is functional (or secondary
to conditions responsible of right ventricle or atrium dila-
tation) in an overwhelming 90–95% of cases as opposed to
the primary aetiology (e.g. trauma, radiation, endocarditis)
[9]. The perceived invasiveness of open surgery and an in-
sufficient consideration of MR and TR to genuinely im-
pact patient survival and symptoms might be reasons for
their insufficient interventional treatment, hence they are
possible targets for research.
We aimed at providing a narrative review of the pub-
lished literature on transcatheter mitral and tricuspid
interventions.
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Main text
Transcatheter mitral valve therapies
Percutaneous mitral commissurotomy for rheumatic mitral
stenosis
The idea of treating the mitral valve disease percutan-
eously dates back to the percutaneous mitral commis-
surotomy (PMC) with the Inoué balloon for severe
symptomatic rheumatic mitral stenosis [10]. PMC is
effective, has a lower procedural morbidity and mortality
than open surgery, and reserves the possibility to re-
intervene in case of recurrence [11]. But eligibility cri-
teria for PMC are strict and if not present open surgery
is to be favoured (Table 1) [11].
Edge-to-edge transcatheter mitral valve plasty
Devices designed for transcatheter treatment of MR have
often been inspired by surgical techniques. Hence,
transcatheter-based devices can be organised into re-
placement and repair techniques [12]. The MitraClip
(MC) device (Abbott Vascular, Santa Clara, CA, USA)
resulted from the adaptation of the surgical Alfieri valvu-
loplasty at the beginning of the century [13–15]. The
clipping device has since been through several iterations
(NT, NTR, XTR) which increased its size, grasping and
maneuverability. Made of cobalt-chromium covered with
polyester, the implant has two arms able to grasp the
two leaflets and is delivered transseptally. It reduces the
mitral regurgitation orifice by “stitching” them together.
Multiple clips can be positioned to maximize results.
The first trial having investigated the efficacy and
safety of the MC device was the EVEREST II random-
ized controlled trial. Were compared the MC to surgery
for the treatment of primary or secondary MR [15].
EVEREST II found that MC was inferior to open mitral
surgery regarding the primary efficacy composite end-
point of freedom from death, surgery for mitral-valve
dysfunction and MR grade ≥ 3+ at 1 year. The primary
endpoint was driven by the need for complementary mi-
tral surgery which was higher in the MCgroup. However,
subgroup analysis suggested that MC could be a better
match for functional MR [15]. At 5 years mortality was
numerically higher in the MC group. Furthermore, more
than one third of patients either had persistent or recur-
rent MR grade ≥ 3+ or mitral surgery. Nevertheless,
interventional guidelines recommendeds transcatheter
edge-to-edge repair for patients with primary [16] and
secondary MR at high risk for surgery [11].
More recently, were published two landmark random-
ized trials that compared MitraClip to medical therapy
alone in patients with severe secondary MR, moderate
left ventricle dysfunction, and suitable anatomy for MC
implantation: COAPT and MITRA-FR trials. In the CO-
APT trial, there was a benefit from the MC at 2 years in
the form of reduced long-term mortality) and rehospital-
ization for heart failure. In the MITRA-FR trial, the rate
of mortality at 1 year was similar for the intervention
and control groups, respectively; the rate of rehospitali-
zation for heart failure was also similar for the interven-
tion and control groups, respectively [17, 18]. One of the
major challenges in both trials was the selection of
patients for inclusion. Both struggled with inclusions
since it took 78 north American centers to include 614
patients in 4.5 years in COAPT (1.7 patients per center
per year), and 3.4 years to 37 French centers to include
304 patients in MITRA-FR (2.4 patients per center per
year). In MITRA-FR one third of the eligible patients
were excluded after enrollment, essentially after echocar-
diographic eligibility assessment. In COAPT 58% of pa-
tient were excluded after enrollment (more patients
were excluded than included), again essentially after
echocardiographic assessment.
Considering both trials together, one might postu-
late that MitraClip might benefit very selected in
whom the functional MR is thought to be responsible
for a worsening left ventricle function, and not solely
the result of a progressive enlargement of the left
ventricle and atrium. Some authors proposed the con-
cept of “tertiary” MR to describe these patients, in
whom MR severity is excessive with regard to a mod-
erate left ventricle dysfunction and dilatation [19].
Consecutively, the upcoming international guidelines
are likely to adopt a COAPT-like approach and
propose criteria for MC aiming at patients with a
“tertiary” functional MR rather than the currently
recommended compassionate approach [11]: moderate
or severe, LVEF 20–50% and left ventricle end-
systolic diameter ≤ 70 mm with symptoms despite
maximally tolerated medical therapy. The results of
the RESHAPE-HF2 (NCT02444338) and MATTER-
HORN trial (NCT02371512) trials might provide
more insight on the prospect of a future for the
MitraClip device for the treatment of functional MR.
It is worth noting that Mitraclip repair is guided by
transoesophageal echocardiography, thus the feasibility
Table 1 Characteristics of unfavourable anatomy for
percutaneous mitral commissurotomy
Wilkins score > 8 (echocardiographic): immobile leaflets, thick mitral
leaflets and sub-valvular apparatus, extensive calcification
Cormier group 3 (imaging): calcification of mitral valve of any extent as
assessed by fluoroscopy
Very small mitral valve area
Non-rheumatic mitral stenosis
Severe tricuspid regurgitation
Left atrial thrombus
Concomitant indications for heart surgery such as coronary artergy
bypass graft
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as well as the result of the procedure are dependent
on the echogenicity of the patient and the skills of
the interventional imager.
The Pascal™ (Edwards Lifesciences) edge-to-edge mi-
tral plasty device is a repositionable and recapturable
system. The device has two paddle-shaped grasping arms
that are independently closable (clasps) as well as a cen-
tral spacer that is intended to fill the regurgitant jet area.
After a favourable initial experience for compassionate
use, PASCAL has been demonstrated to be safe and ef-
fective enough for clinical use in the CLASP prospective
multicenter cohort study. 62 patients have been included
in the CLASP cohort, with both degenerative and func-
tional MR, and observed a low 1.6% cardiovascular mor-
tality, without any stroke events and a 98% rate of < 3+
MR at 30 days [20, 21] (Table 2, Fig. 1).
Transcatheter annuloplasty and chordal plasty
More recent are transcatheter annuloplasty (such as Car-
dioBand™, Edwards Lifesciences) and chordal replace-
ment (such as NeoChord™ NeoChord, Inc.; or Harpoon™
Edwards Lifesciences) systems [23, 25]. The Cardioband
is a flexible implant with multiple anchors which are at-
tached to the annulus, and once they are all fixed, ten-
sions can be applied reducing the dilated annulus to a
physiological size. The device is delivered through a flex-
ible catheter transseptally. A recent publication reported
1-year outcomes after Cardioband implantation in 60
patients with moderate or severe secondary MR treated
in 11 European institutions. While 30-day mortality was
below 5%, the MVARC-defined procedural success was
only of 68%, more than mild MR remained after the pro-
cedure in 30% of patients, reintervention was frequent
during the 1-year follow-up [23, 24]. These data were
consistent of those published on short term outcomes.
Overall, while the safety of the Cardioband device
delivered through transfemoral access seems acceptable,
its reported efficacy regarding durable MR correction re-
mains insufficient. NeoChord and Harpoon are neo-
chordal technologies which attach synthetic new chords
to mitral leaflets and myocardium of the left ventricle.
Both are logically transapically implanted. Observational
data reported low 30-day mortality (< 2%) but remaining
MR grade ≥ 2 in 10 to 35% of patients after the proced-
ure [25–27].
Limitations of transcatheter plasty and the case of
transcatheter replacement
Despite extensive preoperative echocardiographic screen-
ing in the COAPT trial, more than one clip was necessary
in > 60% of patients (≥ three clips in 8% of cases) to
achieve satisfactory reduction of MR [17]. In the EVER-
EST II trial, 5-year data reported that patients included in
the surgical group which comprised essentially patients
with mitral repair, required mitral re-do surgery during
the 5 years of follow-up in 9% of cases. This is higher than
previously suggested in the observational studies [33–35].
Observational studies tend to underestimate outcomes
due to lack of follow-up and underreporting. Furthermore,
randomized trial data on the impossibility of repair and
switching to replacement, as well as the need of reopera-
tion after mitral repair is scarce. Thus, this new estimation
of 9% reoperation 5 years after repair in EVEREST II is to
consider for the ongoing debate of mitral repair versus re-
placement [12]. Indeed, surgical mitral bioprosthetic re-
placement seems to yield a reoperation rate at around 2%
which could be transposable to transcatheter mitral re-
placement [36]. Combining transcatheter repair tech-
niques has been proposed to mitigate the lack of efficacy
on MR resolution; however, this poses the question of in-
creased complication risk and cost [37, 38]. Perhaps valve
replacement could provide a better option.
Transcatheter mitral valve replacement
Mitral repair is favored over replacement for open surgi-
cal treatment of MR in the international guidelines [11].
However, this recommendation is based on observa-
tional data. Recent randomized data showed that re-
placement nearly eliminates the risk of long-term
recurrence of moderate or severe MR at 2 years (58.8%
after repair vs 3.8% after replacement) [39]. By avoiding
the morbidity of open mitral surgery and effectively pre-
venting recurrence of MR, transcatheter mitral valve re-
placement (TMVR) could provide the best option [12].
The first-in-human TMVR was performed in 2012with the
CardiAQ valve (Edwards Lifesciences) [40]. More recently
were published two TMVR feasibility studies. One of them
included patients treated with the Tendyne (Abbott Struc-
tural Heart) device, while the other with the the Intrepid
(Medtronic) transcatheter heart valve. The studies included
Table 2 Short term (in-hospital or 30-days) outcomes of TMVI
devices
Technical success* Mortality MR 2+ or more
Transcatheter repair
MitraClip [22] 178/178 2/178 2/178
Pascal [20] 18/23 3/23 7/19
Cardioband [23, 24] 43/60 3/60 18/57
NeoChord [25, 26] 89/93 1/92 30/92
Harpoon [27] 28/30 0 3/27
Transcatheter replacement
Tendyne [28] 97/100 6/100 21/94
Intrepid [29] 48/50 7/50 0/42
Sapien M3 [30] 9/10 0 1/10
Tiara [31] 17/17 1/17 –
HighLife [32] 9/11 3/11 –
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patients at very high surgical risk and both devices were im-
planted transapically The 30-day mortality rate was 14% with
the Intrepid device and 6% in the Tendyne study (26% at 1
year). However, it is important to notice that the complete
correction of significant MR was constant in both studies
[28, 29, 41]. Following these favorable results, the first trials
aiming at comparing TMVR with to open surgery are already
underway. In the he APOLLO trial (NCT03242642) patients
in the TMVR group will be treated with the Tendyne device,
while in the SUMMIT trial the TMVR device will be the In-
trepid (NCT03433274).
The recent report of a successful first-in-man implant-
ation of the Abbott CEPHEA™ is notable because of the
lack of transseptally implantable transcatheter mitral
valves [42]. The CardioValve Mitral Tech™ is another ex-
ample of this promising technology. Both devices are de-
livered transseptally, which illustrates the urge to develop
transcatheter heart valves (THV) that will be delivered
through a less invasive approach than transapical. Numer-
ous feasibility and safety single-arm studies with other
transapical and transseptal TMVR devices are underway.
It is the case for Edwards EVOQUE™ (NCT02718001),
Neovasc Tiara™ (NCT02276547) and the HighLife™
(NCT02974881).
The first TMVR systems use 32- to 45-F transapical de-
livery catheters which are incompatible with percutaneous
accesses. Thus, adaptation of the technology for transsep-
tal implantation is a major engineering challenge. The
Fig. 1 Transcatheter mitral (a) and tricuspid (b) valve intervention devices with reported clinical use (original image)
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trileaflet Sapien 3 29mm device used in for transcatheter
aortic replacement was previously used transseptally for
valve in ring and valve in valve mitral replacement. Hence,
its manufacturer logically adapted the device for the native
mitral valve (renaming the device Sapien M3), taking ad-
vantage of a decade-long experience in transcatheter aor-
tic interventions and its already developed delivery system.
Given the absence of a solid armature for device anchor-
ing the Sapien M3 THV uses an expandable polytetra-
fluoroethylene–covered nitinol “dock” which allows its
stabilizing by interacting with the mitral subvalvular ap-
paratus. Webb et al. recently published their experience in
a short cohort of 10 patients with primary and/or second-
ary MR and reported a technical success rate of 90%, with-
out stroke or death at 30-days.
It is worth citing the reported experience of TMVR
using TAVI devices (essentially Edwards Sapien family,
and infrequently Boston Lotus). The need for a solid
armature for the THV to be implanted restricted the ex-
perience to “Valve in valve” (VIV) for degenerated mitral
bioprostheses, “valve in ring” (VIR) for mitral disease
after annuloplasty ring surgery and “valve in mitro-
annular calcification” (VIMAC). While results were satis-
factory for VIV TMVR with an approximative 95% tech-
nical success rate, results of VIR and VIMAC are less
appealing with technical success rates of 80 and 62% in
observational cohorts respectively [43]. 30-day mortality
follows a similar pattern: 6, 10 and 35% for VIV, VIR
and VIMAC respectively. The results of VIMAC under-
scored the limited solutions for patients with severe mi-
tral valve disease at high risk for surgery and mitro-
annular calcification. But, recent data on VIMAC TMVR
using THVs designed for the mitral valve, such as the
Tendyne™, have been reported to yield encouraging re-
sults in compassionate cases and is under clinical
investigation.
Furthermore, TMVR carries risks [44]. Although less
frequent with THVs dedicated to the mitral valve (< 1%),
left ventricle outflow tract obstruction (LVOTO) has
been reported in 1/8 patients when aortic THVs devices
were used for TMVR [28–30, 45]. LVOTO is defined by
an increase of 10 mmHg or more of the transaortic gra-
dient [46] and associated with higher mortality [43, 47–
49]. New methods have been proposed as bailout proce-
dures when operators confronted LVOTO. Septal alco-
hol ablation allowed rapid haemodynamic improvement
in most of patients in a short case series of 6 patients
[50]. Rescue laceration of the anterior mitral leaflet
(LAMPOON technique) is another alternative [51, 52].
In a more preventive approach, Wang et al. reported an
increase of the neo-LVOT surface area after pre-emptive
alcohol septal ablation, but at the cost of an increased
risk of major conduction disturbances requiring a per-
manent pacemaker implantation [53].
The challenge of patient selection
Eligibility of patients to transcatheter mitral interven-
tions is often reduced to inoperable or very high pa-
tients for open surgery. However, given the financial
stakes of percutaneous mitral intervention, industry
has been heavily investing in the development of such
technologies [54]. Hence it is likely that new percu-
taneous solutions will become mainstream within the
next 5 years. Then will remain the problem of the
cost of those devices.
However, on the opposite of the aortic valve which
function largely stands for itself, the function of the mitral
valve is intertwined with the anatomy and function of the
left ventricle as well as the left atrium. Mechanisms of mi-
tral regurgitation are often numerous and interconnected,
and the correction of one mechanism might result in the
correction or worsening of another. For instance, the re-
duction of mitral regurgitation might result in reduction
of left ventricle volume (given remodeling is possible) and
hence of the mitral annulus dilatation, overall resulting in
further reduction of mitral regurgitation. On the other
hand, not respecting the mitral sub-valvular apparatus
during surgical mitral replacement is deleterious for left
ventricle geometry and function [55]. Thus, predicting the
effect of a given intervention requires considering its im-
pact on the left heart rather than the mitral valve alone.
Besides, on the contrary of surgical repair involving a
quasi-mandatory association of several repair techniques
(annuloplasty, leaflet plasty, chordal plasty), transcathe-
ter repair devices are very specialized and allow the
treatment of a single mechanism though to be dominant.
Attested by the extensive list of device contra-
indications and incompatibilities, room for adaptation to
an individual patient anatomy is very limited by device
size as well as device and delivery system conformation.
Targeting patients with functional MR who could bene-
fit from Mitraclip has been improved by the publication of
COAPT and MITRA-FR trials. However, such data is
scarce for transcatheter annuloplasty devices and TMVR.
Anatomical compatibility with TMVI devices is of central
importance. TMVI require extensive pre-operative feasi-
bility screening including transesophageal echocardiog-
raphy and MSCT with 3-dimensional reconstructions, to
verify mitral anatomy compatibility and pathway patency.
Finally, the possibility to re-intervene could be crucial
given that device durability remains uncertain for the re-
cent TMVI and TMVR technologies. Transcatheter repair
devices can be combined (i.e. edge-to-edge with annulo-
plasty), however subsequent transcatheter replacement
would become impossible, while valve-in-valve transcathe-
ter replacement remains possible.
As of now, open surgical correction of several coexist-
ing valvulopathies yields the most durable results given
the possibility to efficiently treat them during the same
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intervention. Thus, whenever possible, surgery should be
favoured in operable patients with coexisting mitral and
aortic or tricuspid valve disease [8, 56]. Despite the ab-
sence of robust data, it is largely admitted that in cases
of inoperable patients with severe mitral regurgitation
and secondary severe tricuspid regurgitation, a single
intervention on the mitral valve should be considered
first since its correction could result in a significant re-
duction of the secondary tricuspid regurgitation. If the
impact of the mitral intervention has been insufficient
and symptoms persist a complementary tricuspid inter-
vention can be discussed [57].
Transcatheter tricuspid valve therapies
The tricuspid valve has been traditionally dubbed the “for-
gotten valve”. The heterogeneity of etiologies associated
with TR renders the evaluation of its impact and the im-
pact of its treatment difficult to estimate. Severe primary
TR is a clear indication for surgery but constitutes less
than 10% of TR cases. Despite functional TR being very
frequently observed on echocardiography (> 50%), it is
often only considered for surgical treatment when there is
a concurrent indication for left heart surgery [6, 11, 58].
Although without treatment, TR may progressively deteri-
orate, leading to worse symptoms, biventricular heart fail-
ure and death. In a large retrospective analysis of 5223
patients, Nath et al. showed that moderate and severe TR
is associated with worse survival even when adjusted for
pulmonary artery systolic pressure (PASP), left ventricular
ejection fraction (LVEF), RV size and function [8].
However, evidence that surgical correction of an iso-
lated TR improves survival or symptoms is lacking.
Based on few observational studies international guide-
lines recommend surgical annuloplasty of non-severe TR
with of annulus dilatation ≥40mm or > 21mm/m2 by
2D echocardiography and valve repair or replacement
for severe TR [56]. Tricuspid valve surgery for secondary
symptomatic TR is often performed in small cohorts of
high risk patients, with previous left-heart surgery, in the
form repair or replacement. This yields a high short
term mortality, between 5 and 15% [59–62]. A recent
study by Axtell et showed no survival benefit of surgery
compared to medical therapy in a large cohort of 3276
patients. No difference was identified between repair and
replacement either [63]. However, one of the lessons
learned from COAPT and MITRA-FR trials is that a tai-
lored approach could be very successful [19]. Further-
more, previous studies suggested that tricuspid
annuloplasty allowed right ventricle recovery, reduces
dyspnoea and congestive heart failure [56, 64, 65].
Transcatheter tricuspid valve intervention (TTVI) tech-
niques avoid open surgical morbidity generating condi-
tions such as cardio-pulmonary bypass, sternotomy and
intubation, that might improve peri-operative survival
[12]. Research and industry are currently very active in
this domain [66]. Reported results of TTVI devices are
presented in Table 3.
Transcatheter edge-to-edge and spacer tricuspid technology
As for transcatheter mitral valve therapies, percutaneous
techniques for tricuspid valve intervention were often in-
spired by surgical techniques. The Alfieri-styled edge-to-
edge surgery has been proposed for the tricuspid valve
as well as mitral [74]. A decade long experience with the
MitraClip in the mitral position prompted numerous
operators to attempt TR correction using the MitraClip
in tricuspid position. The best results appear to occur by
attaching the anterior and/or posterior leaflet to the sep-
tal leaflet, which can also reduce annular dimensions.
Clipping the anterior and posterior leaflets is generally
not advised because it may distort the valve and worsen
TR. More recently the “TriClip” was introduced as a
transcatheter tricuspid valve repair system. It is essen-
tially a modification of the MitraClip NT’ percutaneous
delivery system (both owned by Abbott) and was investi-
gated in the TRILUMINATE study (NCT03227757).
The PASCAL device has also been successfully adapted
from mitral to tricuspid use in one case report [75]. How-
ever, data regarding its safety and efficacy are lacking. The
Forma device (Edwards Lifesciences) has been advocated
to reduce TR by creating a new surface for coaptation for
tricuspid leaflets. It consists of a foam-filled spacer, avail-
able in 12 and 15mm both with a length of 42mm, that is
inserted via the subclavian or the axillary vein, placed in
the regurgitant orifice and anchored in the RV apex [76].
The first-in-man experience with 7 patients and a feasibil-
ity study that included 16 patients that showed reduction
in TR. More data is awaited from the ongoing SPACER
study (NCT02787408).
Transcatheter annuloplasty techniques
Nowadays abandoned, the Kay suture annuloplasty con-
sists of excluding the posterior valve leaflet for “bicuspi-
dation” of the tricuspid valve by tightening a suture from
the anteroposterior commissure to the posterior-septal
commissure (“Kay technique”) [77]. Another technique
uses two parallel lines of running sutures starting at
posterior-septal commissure at the annulus level with a
stich to the fibrous trigone to narrow the tricuspid annu-
lus (“De Vega technique”) [78]. Those surgical annulo-
plasty techniques have been imitated by the TriAlign
and TriCinch devices [79, 80]. The Trialign device is a
transcatheter suture annuloplasty technique performed
transjugularly. An insulated radiofrequency wire is ad-
vanced into the right ventricle to then retrogradely cross
the tricuspid annulus tissue. Thereafter, two pledgets are
placed at the posteroseptal as well as the anteroposterior
commissures, which are then cinched to obliterate the
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posterior tricuspid leaflet, yielding a “bicuspidisation” of
the tricuspid valve [79, 81].
The TriCinch device is delivered through the femoral
vein. It presents an epicardial coil with two haemostasis
seals implanted in the mid-anterior part of the tricuspid
annulus, a nitinol stent connected to the coil through a
Dacron band, is placed in the inferior vena cava (IVC),
to maintain tension applied to the annulus. TriCinch
clinical use has only been described in small case series
[82–84]. The ring annuloplasty technique is the cur-
rently preferred by most teams and uses rigid or semi-
rigid rings, planar or non-planar to fit the tricuspid anat-
omy [85, 86]. The transcatheter equivalent ring annulo-
plasty can be performed with the Cardioband (also used
for mitral annuloplasty) or Millipede devices.
Transcatheter tricuspid valve replacement
Only bioprosthetic valves can be implanted percutan-
eously. Existing THVs usually used for pulmonary sten-
osis (Melody) and aortic stenosis (Sapien family) have
been used for degenerated tricuspid bioprostheses for
many years, with a 30-day mortality of 3.2% in the lar-
gest registry to date [87]. However, in the absence of
solid armature, these devices cannot be used for native
tricuspid valves. Existing dedicated TTVR devices are
intended to be implanted in a orthotopic or heterotopic
positions. The proximity of conduction pathways render
complete atrioventricular block one of the expected
main complications of TTVR.
The NAVIGATE (NaviGate Cardiac Structures) trans-
catheter heart valve (THV) is a self-expanding bio-
prosthesis for orthotopic tricuspid valve replacement
(TTVR) that consists of three xenogeneic pericardial
leaflets seated in a tapered nitinol stent with atrial wing-
lets and ventricular graspers for anchoring the tricuspid
annulus and leaflets without protruding into adjacent
chambers. NAVIGATE is available in four sizes intended
for TA diameters ranging from 36mm to 52mm. A 42
Fr introducer sheath is used to deliver the valve through
a transjugular pathway (or through transatrial minimally
invasive right thoracotomy surgical approach). The
NAVIGATE is currently the only clinically available
TTVR device. The delivery system features two degrees
of motion at the tip and allows for a 90° angulation [88,
89]. As of yet, only two short case series have been pub-
lished [88, 90]. Hence clinical implementation remains
at its infancy but has interesting potential. Nevertheless,
design improvement needs to reduce sheath size and
deliverability.
TricValve is in fact a set of two self-expandable het-
erotopic THVs with each having nitinol frames, and dif-
ferent designs because intended to be deployed into
superior and inferior vena cava respectively, at cavo-
atrial inflow. TricValve does not require a pre-stenting
of caval veins and available sizes from 28mm to 43mm.
Few patients have so far been reported to have received
TricValve, and since it does not treat the TR per se, its
intended use beyond compassionate for symptomatic re-
lief is uncertain [91].
Other devices include TriSol (TriSol Medical), Lux
(Jenscare Biotechnology), TRiCares (TRiCares SAS,
Paris, France) TTVR devices which are yet to be used in
clinical setting. Both devices are orthotopic and self-
expanding with bovine pericardial tissue mounted on a
nitinol stent frame. The TriSol holds a single bovine
pericardial structure with a single dome-shaped leaflet
which is attached in two opposite central commissures
to create a bileaflet valve. The xenograft is mounted on
a self-expanding conical nitinol stent featuring a ven-
tricular skirt of porcine pericardium and an atrial polyes-
ter skirt. Anchoring is performed through axial force to
reduce the risk of conduction disturbance. The resulting
prosthesis is retrievable and repositionable. Its 30 Fr de-
livery system is intended to be used through a jugular
vein access to allow an implantation alignment with the
tricuspid valve [92]. The clinical applicability of these de-
vices is yet to be investigated.
Conclusions
Transcatheter mitral valve therapy is nowadays an estab-
lished solution for high surgical risk patients with mitral
regurgitation and those suffering from rheumatic mitral
stenosis. Benefit of transcatheter mitral edge-to-edge re-
pair in secondary mitral regurgitation has been recently
established in selected patients. However, transcatheter
repair as well as replacement are yet to be proven
Table 3 Short term (in-hospital or 30-days) outcomes of TTVI devices
Trial/study Technical successa Mortality TR volume reduction (mL)
TriAlign SCOUT I [67] NCT02574650 SCOUT II is enrolling 12/15 0 −2.7 ± 39.5
TriCinch Giannini and Colombo [66] PREVENT ongoing NCT03632967 20/24 – –
Cardioband TRI-REPAIR [68] TriBAND ongoing NCT03779490 28/30 2/30 −35.6 ± 35.3
MitraClip and TriClip Nickenig et al. [69] TRILUMINATE NCT03227757 [70] 6/64
10/85
3/64
0
−26.4 ± 7.8
− 18.6 ± 21.2
FORMA Perlman and Dvir [71–73] SPACER enrolling NCT02787408 – 2/47 –
a no standardized definition for “technical success” for TTVI
Overtchouk et al. BMC Cardiovascular Disorders            (2020) 20:1 Page 7 of 10
effective for primary mitral regurgitation. Nevertheless,
numerous ongoing trials are promised to shed light on
the how much of the promises of those technologies will
be met with reality. And if benefit is proven, additional
research will be needed to establish whether mitral re-
pair and replacement should be opposed or used in
complementarity, notably with regards to device com-
patibility with the anatomy of individual patients. Trans-
catheter repair as compared to surgical repair, is often
limited by the specialisation of the device which will
treat a single of often associated mechanisms of mitral
regurgitation. Transcatheter replacement requires larger
delivery systems, comes with a limited number of device
sizes and conveys the risk of left ventricle outflow tract
obstruction. Adaptation of a device comes with major fi-
nancial constraints, hence in the future some patients
with infrequent anatomy could still only be served with
open surgery.
Clinical implementation of transcatheter tricuspid ther-
apies is still at its infancy. The development of the field
has likely been delayed by a lack of recognized impact of
tricuspid regurgitation on symptoms and prognosis. How-
ever, it now constitutes a promising alternative for pa-
tients with isolated secondary tricuspid regurgitation to a
possibly morbid open surgery. But all the steps of develop-
ment of a new valve technology (including safety, efficacy,
optimal patient selection) remain to be followed for trans-
catheter tricuspid interventions.
Given the complexity of mitral and tricuspid valve disease
and the increasingly large armamentarium to treat them,
Heart Team discussion remains the main guarantor that
every patient is offered the optimal solution for her/him
based on contemporary evidence-based argumentation.
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